

ASH 2020: Therapeutic developments in ALL, NHL, and MM

Faculty

C. Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, USA

John P. Leonard, MD, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY, USA

Wendy Stock, MD, University of Chicago, Chicago, IL, USA

Release date: April 30, 2021

Expiration date: April 30, 2022

Estimated time to complete activity: 1.0 hours

Available CME Credits: 1 AMA PRA Category 1 Credit(s)TM

Activity description

This webcast is a virtual roundtable discussion covering the highlights of the 62nd ASH Annual Meeting and Exposition (ASH 2020) in acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and multiple myeloma (MM). The aim of this activity is to educate healthcare professionals (HCPs) responsible for the diagnosis, treatment, or management of patients with these malignancies. Accordingly, leading experts discussed key and emerging data presented at ASH 2020 and provided an expert commentary on the relevance and implications for clinical practice in each indication.

Target audience

This activity is intended for US and ex-US hematologists, oncologists, pathologists, and other HCPs responsible for the diagnosis, treatment, or management of patients with ALL, NHL, or MM

Educational objectives

After completing this activity, the participant should be better able to:

- Describe the mechanism of action of novel and emerging treatments for the management of hematologic malignancies (including ALL, NHL, and MM) as presented at the 62nd ASH Annual Meeting and Exposition (ASH 2020)
- Discuss the latest clinical trial data (efficacy, safety, tolerability) for the diagnosis and treatment of hematologic malignancies (including ALL, NHL, and MM) as presented at ASH 2020
- Apply data-driven strategies to improve treatment selection and manage treatment-related toxicities in patients with ALL, NHL, and MM, based on the review of the data presented at ASH 2020

Joint accreditation statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Ology Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the

Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

Physician continuing medical education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of participation and request for credit

There are no fees for participating in, and receiving CME/CE credit for, this activity.

In order to claim credit, participants must complete the following procedures during the period April 30, 2021 through April 30, 2022.

1. Read the educational objectives, accreditation information, and faculty disclosures
2. View the webcast
3. Take the post-activity test and complete the evaluation
4. Download the certificate of CME credit

Disclosure of conflicts of interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

| Faculty | Relationship identified with |
|--------------------------|---|
| C. Ola Landgren, MD, PhD | Consultant for: Adaptive Biotechnologies, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno Pfizer Fees for non-CE services received directly from an ineligible entity or their agents: Amgen, BMS, Adaptive Biotechnologies Independent data monitoring committee member for: Takeda, Merck, Janssen |

| | |
|---------------------|--|
| John P. Leonard, MD | Consultant for: Sutro Biopharma, Miltenyi Biotec, AstraZeneca, Epizyme, BMS/Celgene, Regeneron, Bayer, Gilead Kite, Karyopharm Therapeutics, GenMab, Genentech/Roche, AbbVie, Incyte, MEI Pharma, ADC Therapeutics |
| Wendy Stock, MD | Royalty fees from: UpToDate Consultant for: Agios, Jazz Pharmaceuticals, Kite Pharma, Kura Oncology, MorphoSys, Servier and Pfizer, Amgen Speaking royalties for: AbbVie |

Planners and managers

The PIM planners and managers have nothing to disclose. The Ology Medical Education planners and managers have nothing to disclose.

Provider information

Jointly provided by Postgraduate Institute for Medicine and Ology Medical Education.



Financial support

This activity is supported by an independent educational grant from Amgen Inc.

Disclosure of unlabeled use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The course materials are for educational purposes only and should not be reproduced or distributed in any way. If you wish to reproduce, store in a retrieval system, transmit in

any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, any part of the material presented, you will need to obtain all the necessary permissions by writing to the publisher, the original author, or any other current copyright owner.

Contact information for questions about the activity

info@ologyeducation.org, www.ologyeducation.org
inquiries@pimed.com, www.pimed.com

Policy on privacy and confidentiality

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

System requirements

Ology Education requires a modern web browser (Google Chrome, Mozilla Firefox, Apple Safari, Microsoft Edge). Certain educational activities may require a PDF reader such as Adobe Acrobat Reader to view.

Media

Internet